ScholarIQanswers from OpenAlex & ORCID
Tobias Wirenfeldt Klausen
ResearcherPublications, citations & collaboration network
Tobias Wirenfeldt Klausen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Tobias Wirenfeldt Klausen have?
ScholarIQindexed works
Tobias Wirenfeldt Klausen has 219 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Tobias Wirenfeldt Klausen have?
ScholarIQcitation count
Tobias Wirenfeldt Klausen has 5,110 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Tobias Wirenfeldt Klausen?
ScholarIQh-index
Tobias Wirenfeldt Klausen has an h-index of 40 in OpenAlex.
What is the i10-index of Tobias Wirenfeldt Klausen?
ScholarIQi10-index
Tobias Wirenfeldt Klausen has an i10-index of 106 in OpenAlex.
What is the ORCID of Tobias Wirenfeldt Klausen?
ScholarIQorcid
The ORCID for Tobias Wirenfeldt Klausen is on the source record.
What is the OpenAlex record for Tobias Wirenfeldt Klausen?
ScholarIQopenalex
The OpenAlex for Tobias Wirenfeldt Klausen is on the source record.
What are the most-cited papers on Tobias Wirenfeldt Klausen?
ScholarIQmost cited works
Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
N. Toft, Henrik Birgens, Jonas Abrahamsson, Laimonas Griškevičius, Heléne Hallböök, Mats Heyman, Tobias Wirenfeldt Klausen, ÓG Jónsson, Katrin Palk, Kaie Pruunsild, Petter Quist‐Paulsen, Goda Vaitkevičienė, Kim Vettenranta, Arne Åsberg, Thomas Leth Frandsen, Hanne Vibeke Marquart, Hans O. Madsen, Ulrika Norén‐Nyström, Kjeld Schmiegelow
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebæk, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, Morten Orebo Holmström, Helle Westergren Hendel, E. Ehrnrooth, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen, Inge Marie Svane
Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients
Claudia Schöllkopf, Lars Kjeldsen, Ole Weiss Bjerrum, Hans Torben Mourits‐Andersen, Johan Lanng Nielsen, Bjarne Christensen, Bjarne Anker Jensen, Bjarne Bach Pedersen, Ellen Taaning, Tobias Wirenfeldt Klausen, Henrik Birgens
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia
Sif Gudbrandsdottir, Henrik Birgens, Henrik Frederiksen, Bjarne Anker Jensen, Morten Krogh Jensen, Lars Kjeldsen, Tobias Wirenfeldt Klausen, Herdis Larsen, Hans Torben Mourits‐Andersen, Claus Henrik Nielsen, Ove Juul Nielsen, Torben Plesner, Stanislaw Pulczynski, Inge Helleberg Rasmussen, Dorthe Rønnov‐Jessen, Hans Carl Hasselbalch
A phase <scp>III</scp> randomized trial comparing glucocorticoid monotherapy <i>versus</i> glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia
Henrik Birgens, Henrik Frederiksen, Hans Carl Hasselbalch, Inge Helleberg Rasmussen, Ove Juul Nielsen, Lars Kjeldsen, Herdis Larsen, Torben Mourits‐Andersen, Torben Plesner, Dorthe Rønnov‐Jessen, Hanne Vestergaard, Tobias Wirenfeldt Klausen, Claudia Schöllkopf